Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2225709,plasma half-life,"However, the plasma half-life of demethyldiazepam was longer in poor metabolizers than in extensive metabolizers of mephenytoin (mean +/- SD: 161 +/- 37 and 116 +/- 29 hours, respectively; p less than 0.02).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,161,402,DB00532,Mephenytoin
,2225709,plasma half-life,"However, the plasma half-life of demethyldiazepam was longer in poor metabolizers than in extensive metabolizers of mephenytoin (mean +/- SD: 161 +/- 37 and 116 +/- 29 hours, respectively; p less than 0.02).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,116,403,DB00532,Mephenytoin
,2225709,plasma half-life,"The mean plasma half-life values of diazepam in Chinese extensive metabolizers (85.1 hours) and poor metabolizers (88.3 hours) were very similar to those in white subjects who were poor metabolizers (88.3 hours), and more than twice those in white subjects who were extensive metabolizers (40.8 hours).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,85.1,404,DB00532,Mephenytoin
,2225709,plasma half-life,"The mean plasma half-life values of diazepam in Chinese extensive metabolizers (85.1 hours) and poor metabolizers (88.3 hours) were very similar to those in white subjects who were poor metabolizers (88.3 hours), and more than twice those in white subjects who were extensive metabolizers (40.8 hours).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,88.3,405,DB00532,Mephenytoin
,2225709,plasma half-life,"The mean plasma half-life values of diazepam in Chinese extensive metabolizers (85.1 hours) and poor metabolizers (88.3 hours) were very similar to those in white subjects who were poor metabolizers (88.3 hours), and more than twice those in white subjects who were extensive metabolizers (40.8 hours).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,40.8,406,DB00532,Mephenytoin
,23777257,Km,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,33,1718,DB00532,Mephenytoin
,23777257,Vmax,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),1/[min],0.20,1719,DB00532,Mephenytoin
,23777257,inhibition constant,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,37,1720,DB00532,Mephenytoin
,23777257,maximum plasma concentration,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,10.5,1721,DB00532,Mephenytoin
<,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.3,12075,DB00532,Mephenytoin
>,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.8,12076,DB00532,Mephenytoin
,7974621,half-life,"In nine subjects, carisoprodol was rapidly eliminated, with a mean half-life of 99 +/- 46 min, and extensively converted to meprobamate.",Carisoprodol elimination in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974621/),min,99,19512,DB00532,Mephenytoin
,7974621,overall half-life,"One subject eliminated carisoprodol with an overall half-life of 376 min, and only small amounts of meprobamate were recorded.",Carisoprodol elimination in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974621/),min,376,19513,DB00532,Mephenytoin
,7974621,protein binding,"In spiked human sera, protein binding of carisoprodol was in the range of 41-67%, whereas meprobamate was bound to a lesser extent, 14-24%.",Carisoprodol elimination in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974621/),%,41-67,19514,DB00532,Mephenytoin
,7974621,protein binding,"In spiked human sera, protein binding of carisoprodol was in the range of 41-67%, whereas meprobamate was bound to a lesser extent, 14-24%.",Carisoprodol elimination in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974621/),%,14-24,19515,DB00532,Mephenytoin
,15145965,MR,"Among the subjects, there was a gene-dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt/wt, n = 9), heterozygous extensive metabolizers (wt/m1 or wt/m2, n = 10), and poor metabolizers (m1/m1 or m1/m2, n = 7).",Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145965/),,1.76,26653,DB00532,Mephenytoin
,15145965,MR,"Among the subjects, there was a gene-dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt/wt, n = 9), heterozygous extensive metabolizers (wt/m1 or wt/m2, n = 10), and poor metabolizers (m1/m1 or m1/m2, n = 7).",Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145965/),,3.45,26654,DB00532,Mephenytoin
,15145965,MR,"Among the subjects, there was a gene-dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt/wt, n = 9), heterozygous extensive metabolizers (wt/m1 or wt/m2, n = 10), and poor metabolizers (m1/m1 or m1/m2, n = 7).",Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145965/),,33.08,26655,DB00532,Mephenytoin
,925954,plasma half-life,"The l-form exhibited a longer plasma half-life (23.3 +/- S.E. 1.0 hour) than the d-form (16.3 +/- 1.0 hour, P less than .005).","Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/925954/),h,23.3,35891,DB00532,Mephenytoin
,925954,plasma half-life,"The l-form exhibited a longer plasma half-life (23.3 +/- S.E. 1.0 hour) than the d-form (16.3 +/- 1.0 hour, P less than .005).","Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/925954/),h,16.3,35892,DB00532,Mephenytoin
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],3,36204,DB00532,Mephenytoin
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],1,36205,DB00532,Mephenytoin
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],5,36206,DB00532,Mephenytoin
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],3,36207,DB00532,Mephenytoin
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],1,36208,DB00532,Mephenytoin
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],5,36209,DB00532,Mephenytoin
>,8619446,Recoveries,Recoveries of the analytes and the internal standard (pyrimethamine) were > 62% from plasma and > 77% from urine.,"Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),%,62,36210,DB00532,Mephenytoin
>,8619446,Recoveries,Recoveries of the analytes and the internal standard (pyrimethamine) were > 62% from plasma and > 77% from urine.,"Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),%,77,36211,DB00532,Mephenytoin
,3720699,half-lives,"The half-lives of R-PEH ranged from 77.7 to 175.8 h, and correlated closely with the creatinine clearance.",Pharmacokinetics of R-enantiomeric normephenytoin during chronic administration in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720699/),h,77.7 to 175.8,64078,DB00532,Mephenytoin
,8981384,elimination half-life,Although the mean elimination half-life was significantly shorter in the smoker group (p < .01) than in the nonsmoker group (13.1 +/- 2.9 vs.,Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8981384/),,13.1,70523,DB00532,Mephenytoin
,12695344,"K(i,ub)","K(i,total) values varied with microsomal protein concentration, whereas the corresponding K(i,ub) values were within a narrow range (70-80 nM).",Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695344/),nM,70-80,71464,DB00532,Mephenytoin
,12695344,K(i)iv,"The mean (+/-S.D.) values of K(i)iv based on total and unbound plasma concentrations were 13.5 +/- 5.6 and 1.9 +/- 1.1 nM, respectively.",Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695344/),nM,13.5,71465,DB00532,Mephenytoin
,12695344,K(i)iv,"The mean (+/-S.D.) values of K(i)iv based on total and unbound plasma concentrations were 13.5 +/- 5.6 and 1.9 +/- 1.1 nM, respectively.",Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695344/),nM,1.9,71466,DB00532,Mephenytoin
,9174682,areas under the serum concentration-time curve,Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1).,Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174682/),[h·μM] / [l],1.31,72340,DB00532,Mephenytoin
,9174682,areas under the serum concentration-time curve,Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1).,Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174682/),[h·μM] / [l],1.00,72341,DB00532,Mephenytoin
,9579299,Vmax,"But divided into genotype groups, Vmax values were 3.9 +/- 0.4, 5.3 +/- 0.7, and 5.7 +/- 1.4 mg/kg/day for the patients with the m2 allele, with the m1 allele, and with neither the m1 or m2 allele, respectively.",The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579299/),[mg] / [d·kg],3.9,73533,DB00532,Mephenytoin
,9579299,Vmax,"But divided into genotype groups, Vmax values were 3.9 +/- 0.4, 5.3 +/- 0.7, and 5.7 +/- 1.4 mg/kg/day for the patients with the m2 allele, with the m1 allele, and with neither the m1 or m2 allele, respectively.",The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579299/),[mg] / [d·kg],5.3,73534,DB00532,Mephenytoin
,9579299,Vmax,"But divided into genotype groups, Vmax values were 3.9 +/- 0.4, 5.3 +/- 0.7, and 5.7 +/- 1.4 mg/kg/day for the patients with the m2 allele, with the m1 allele, and with neither the m1 or m2 allele, respectively.",The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579299/),[mg] / [d·kg],5.7,73535,DB00532,Mephenytoin
,17517049,K(m),"Microsomes from six human livers converted Gz to its 6beta-OHGz, 7beta-OHGz, and MeOH-Gz metabolites, with respective mean (+/- SD) K(m) values of 461 +/- 139, 404 +/- 143 and 334 +/- 75 microm and mean V(max) values of 130 +/- 55, 82 +/- 31 and 268 +/- 115 pmol min(-1) mg(-1), respectively.",Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517049/),μm,461,86784,DB00532,Mephenytoin
,17517049,K(m),"Microsomes from six human livers converted Gz to its 6beta-OHGz, 7beta-OHGz, and MeOH-Gz metabolites, with respective mean (+/- SD) K(m) values of 461 +/- 139, 404 +/- 143 and 334 +/- 75 microm and mean V(max) values of 130 +/- 55, 82 +/- 31 and 268 +/- 115 pmol min(-1) mg(-1), respectively.",Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517049/),μm,404,86785,DB00532,Mephenytoin
,17517049,K(m),"Microsomes from six human livers converted Gz to its 6beta-OHGz, 7beta-OHGz, and MeOH-Gz metabolites, with respective mean (+/- SD) K(m) values of 461 +/- 139, 404 +/- 143 and 334 +/- 75 microm and mean V(max) values of 130 +/- 55, 82 +/- 31 and 268 +/- 115 pmol min(-1) mg(-1), respectively.",Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517049/),μm,334,86786,DB00532,Mephenytoin
,17517049,V(max),"Microsomes from six human livers converted Gz to its 6beta-OHGz, 7beta-OHGz, and MeOH-Gz metabolites, with respective mean (+/- SD) K(m) values of 461 +/- 139, 404 +/- 143 and 334 +/- 75 microm and mean V(max) values of 130 +/- 55, 82 +/- 31 and 268 +/- 115 pmol min(-1) mg(-1), respectively.",Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517049/),[pM] / [mg·min],130,86787,DB00532,Mephenytoin
,17517049,V(max),"Microsomes from six human livers converted Gz to its 6beta-OHGz, 7beta-OHGz, and MeOH-Gz metabolites, with respective mean (+/- SD) K(m) values of 461 +/- 139, 404 +/- 143 and 334 +/- 75 microm and mean V(max) values of 130 +/- 55, 82 +/- 31 and 268 +/- 115 pmol min(-1) mg(-1), respectively.",Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517049/),[pM] / [mg·min],82,86788,DB00532,Mephenytoin
,17517049,V(max),"Microsomes from six human livers converted Gz to its 6beta-OHGz, 7beta-OHGz, and MeOH-Gz metabolites, with respective mean (+/- SD) K(m) values of 461 +/- 139, 404 +/- 143 and 334 +/- 75 microm and mean V(max) values of 130 +/- 55, 82 +/- 31 and 268 +/- 115 pmol min(-1) mg(-1), respectively.",Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517049/),[pM] / [mg·min],268,86789,DB00532,Mephenytoin
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB00532,Mephenytoin
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB00532,Mephenytoin
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB00532,Mephenytoin
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB00532,Mephenytoin
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB00532,Mephenytoin
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB00532,Mephenytoin
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],482,108437,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],206,108438,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],167,108439,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],<,108440,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],100,108441,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],3160,108442,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],2430,108443,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],937,108444,DB00532,Mephenytoin
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],534,108445,DB00532,Mephenytoin
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],1660,108446,DB00532,Mephenytoin
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],7715 to 15319,108447,DB00532,Mephenytoin
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.40,109827,DB00532,Mephenytoin
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.33,109828,DB00532,Mephenytoin
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.61,116091,DB00532,Mephenytoin
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.82,116092,DB00532,Mephenytoin
,4032286,oral clearance,"In the EM subjects, the disposition of S- and R-mephenytoin was markedly different with a 100- to 200-fold difference in mean oral clearance (4.7 vs. 0.027 liters/min) and a 30- to 40-fold difference in elimination half-life (2.1 vs. 76 hr).",Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032286/),[l] / [min],4.7,116866,DB00532,Mephenytoin
,4032286,oral clearance,"In the EM subjects, the disposition of S- and R-mephenytoin was markedly different with a 100- to 200-fold difference in mean oral clearance (4.7 vs. 0.027 liters/min) and a 30- to 40-fold difference in elimination half-life (2.1 vs. 76 hr).",Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032286/),[l] / [min],0.027,116867,DB00532,Mephenytoin
,4032286,elimination half-life,"In the EM subjects, the disposition of S- and R-mephenytoin was markedly different with a 100- to 200-fold difference in mean oral clearance (4.7 vs. 0.027 liters/min) and a 30- to 40-fold difference in elimination half-life (2.1 vs. 76 hr).",Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032286/),h,2.1,116868,DB00532,Mephenytoin
,4032286,elimination half-life,"In the EM subjects, the disposition of S- and R-mephenytoin was markedly different with a 100- to 200-fold difference in mean oral clearance (4.7 vs. 0.027 liters/min) and a 30- to 40-fold difference in elimination half-life (2.1 vs. 76 hr).",Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032286/),h,76,116869,DB00532,Mephenytoin
,4032286,apparent half-life,"In these same subjects, R-PEH concentrations significantly accumulated over several days and then very slowly declined with an apparent half-life of about 200 hr.",Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4032286/),h,200,116870,DB00532,Mephenytoin
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,5.0,119549,DB00532,Mephenytoin
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,4.0,119550,DB00532,Mephenytoin
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,20,119551,DB00532,Mephenytoin
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,15,119552,DB00532,Mephenytoin
,2910639,R/S ratios,"The R/S ratios for the clearance to 4-OH-P were similar between EM and PMD (2.5 +/- 0.5 vs 2.5 +/- 0.4, respectively), implying that the different enzymes involved in ring hydroxylation (i.e., the debrisoquin isozyme and other hydroxylases) have similar stereoselective preferences.",Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910639/),,2.5,125387,DB00532,Mephenytoin
,2910639,R/S ratios,"The R/S ratios for the clearance to 4-OH-P were similar between EM and PMD (2.5 +/- 0.5 vs 2.5 +/- 0.4, respectively), implying that the different enzymes involved in ring hydroxylation (i.e., the debrisoquin isozyme and other hydroxylases) have similar stereoselective preferences.",Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910639/),,2.5,125388,DB00532,Mephenytoin
,1505152,percentage exhalation,"The mean percentage exhalation of the 13C test dose, as determined by 13CO2 in breath during 8 hours, was 23.0% +/- 8.0% (n = 18) before treatment.",Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505152/),%,23.0,137108,DB00532,Mephenytoin
,1505152,exhalation rates,In both groups exhalation rates of 13CO2 returned to near pretreatment values within the 7-day washout period (24.2% +/- 7.8%; n = 17).,Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505152/),%,24.2,137109,DB00532,Mephenytoin
,8866915,urinary recovery,4. The urinary recovery of PG ranged from 30 to 69% of the dose and for CG from 2.8 to 32% of the dose.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),%,30 to 69,137684,DB00532,Mephenytoin
,8866915,urinary recovery,4. The urinary recovery of PG ranged from 30 to 69% of the dose and for CG from 2.8 to 32% of the dose.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),%,2.8 to 32,137685,DB00532,Mephenytoin
,8866915,overall urinary recovery,The overall urinary recovery of PG plus CG ranged from 54 to 77% of the dose.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),%,54 to 77,137686,DB00532,Mephenytoin
,8866915,AUC,The AUC for PG ranged from 3.2 to 9.5 mg l-1 h whereas for CG it was from 0.02 to 0.71 mg l-1 h.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),[h·mg] / [l],3.2 to 9.5,137687,DB00532,Mephenytoin
,8866915,AUC,The AUC for PG ranged from 3.2 to 9.5 mg l-1 h whereas for CG it was from 0.02 to 0.71 mg l-1 h.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),[h·mg] / [l],0.02 to 0.71,137688,DB00532,Mephenytoin
,8866915,partial intrinsic clearance,The partial intrinsic clearance to CG ranged 25-fold from 0.41 to 10.1 l h-1.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),[l] / [h],0.41 to 10.1,137689,DB00532,Mephenytoin
,9333103,total clearance,"During fluvoxamine use, the median of the total clearance of chloroguanide decreased in a statistically significant way from 1282 ml/min to 782 ml/min among the extensive metabolizers, whereas there was no change among the poor metabolizers.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],1282,142096,DB00532,Mephenytoin
,9333103,total clearance,"During fluvoxamine use, the median of the total clearance of chloroguanide decreased in a statistically significant way from 1282 ml/min to 782 ml/min among the extensive metabolizers, whereas there was no change among the poor metabolizers.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],782,142097,DB00532,Mephenytoin
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],222,142098,DB00532,Mephenytoin
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],97,142099,DB00532,Mephenytoin
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],33,142100,DB00532,Mephenytoin
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],11,142101,DB00532,Mephenytoin
,1505151,plasma half-life,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,91.0,149357,DB00532,Mephenytoin
,1505151,plasma half-life,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,59.7,149358,DB00532,Mephenytoin
,1505151,clearance,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),[ml] / [min],9.4,149359,DB00532,Mephenytoin
,1505151,clearance,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),[ml] / [min],17.0,149360,DB00532,Mephenytoin
,1505151,plasma half-life,"In addition, the plasma half-life of demethyldiazepam showed a statistically significant (p less than 0.001) difference between the extensive metabolizers (95.9 +/- 11.3 hours) and poor metabolizers (213.1 +/- 10.7 hours), and correlated with the log10 urinary excretion of 4-hydroxymephenytoin (rs = -0.615, p less than 0.01).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,95.9,149361,DB00532,Mephenytoin
,1505151,plasma half-life,"In addition, the plasma half-life of demethyldiazepam showed a statistically significant (p less than 0.001) difference between the extensive metabolizers (95.9 +/- 11.3 hours) and poor metabolizers (213.1 +/- 10.7 hours), and correlated with the log10 urinary excretion of 4-hydroxymephenytoin (rs = -0.615, p less than 0.01).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,213.1,149362,DB00532,Mephenytoin
,2633921,clearances,"The mean +/- SD intravenous clearances of R- and S-mephenytoin were 1630 +/- 250 ml/hr and 630 +/- 250 ml/hr, respectively.",Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633921/),[ml] / [h],1630,150432,DB00532,Mephenytoin
,2633921,clearances,"The mean +/- SD intravenous clearances of R- and S-mephenytoin were 1630 +/- 250 ml/hr and 630 +/- 250 ml/hr, respectively.",Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633921/),[ml] / [h],630,150433,DB00532,Mephenytoin
,2633921,portal vein clearances,The corresponding portal vein clearances for these enantiomers were 2560 +/- 1230 ml/hr (R-mephenytoin) and 540 +/- 230 ml/hr (S-mephenytoin).,Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633921/),[ml] / [h],2560,150434,DB00532,Mephenytoin
,2633921,portal vein clearances,The corresponding portal vein clearances for these enantiomers were 2560 +/- 1230 ml/hr (R-mephenytoin) and 540 +/- 230 ml/hr (S-mephenytoin).,Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633921/),[ml] / [h],540,150435,DB00532,Mephenytoin
,8971425,Cmax,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],59,155308,DB00532,Mephenytoin
,8971425,"AUC (0, th)","4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],144,155309,DB00532,Mephenytoin
,8971425,Cmax,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],183,155310,DB00532,Mephenytoin
,8971425,AUC,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],2627,155311,DB00532,Mephenytoin
,8971425,Cmax,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],356,155312,DB00532,Mephenytoin
,8971425,AUC,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],10512,155313,DB00532,Mephenytoin
,12102670,area under the curve (AUC) ratio,"In nine of the 12 patients, PHT plasma concentrations remained stable, with a mean (+/-SD) area under the curve (AUC) ratio (combination therapy/monotherapy) of 1.13 +/- 0.17 (range, 0.89-1.23).",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.13,155947,DB00532,Mephenytoin
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.25,155948,DB00532,Mephenytoin
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.39,155949,DB00532,Mephenytoin
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.55,155950,DB00532,Mephenytoin
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],15 to 21,155951,DB00532,Mephenytoin
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],28 to 36,155952,DB00532,Mephenytoin
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],27 to 41,155953,DB00532,Mephenytoin
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],5036,156158,DB00532,Mephenytoin
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],2854,156159,DB00532,Mephenytoin
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],3255,156160,DB00532,Mephenytoin
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],2125,156161,DB00532,Mephenytoin
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],1069,156162,DB00532,Mephenytoin
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],841,156163,DB00532,Mephenytoin
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],947,156164,DB00532,Mephenytoin
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],771,156165,DB00532,Mephenytoin
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],99,169598,DB00532,Mephenytoin
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],56,169599,DB00532,Mephenytoin
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],66,169600,DB00532,Mephenytoin
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],43,169601,DB00532,Mephenytoin
,8823233,area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity],"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·μM] / [l],7.53,176901,DB00532,Mephenytoin
,8823233,area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity],"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·μM] / [l],12.80,176902,DB00532,Mephenytoin
,8823233,oral clearance,"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[ml] / [min],319,176903,DB00532,Mephenytoin
,8823233,oral clearance,"Omeprazole concentrations were significantly lower (mean area under the plasma concentration time curve extrapolated to infinity [AUCO-infinity] +/- SEM; 7.53 +/- 1.21 versus 12.80 +/- 2.13 mumol.hr.L-1, respectively; p < 0.05) and its oral clearance greater (319 +/- 60 versus 183 +/- 35 ml/min, respectively; p < 0.05) in the white subjects than in the Chinese subjects.",Ethnic and genetic determinants of omeprazole disposition and effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[ml] / [min],183,176904,DB00532,Mephenytoin
,8823233,AUCgas24,"Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]).",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·pM] / [l],334,176905,DB00532,Mephenytoin
,8823233,AUCgas24,"Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]).",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·pM] / [l],1414,176906,DB00532,Mephenytoin
,8823233,AUCgas24,"Fasting gastrin, AUCgas12, and AUCgas24 were significantly greater in the Chinese subjects than in the white subjects (30.0 +/- 6.4 versus 14.4 +/- 1.2 pmol, respectively [p < 0.02]; 661 +/- 114 versus 334 +/- 38 pmol.hr.L-1, respectively [p < 0.002]; and 1414 +/- 228 versus 747 +/- 99 pmol.hr.L-1, respectively [p < 0.004]).",Ethnic and genetic determinants of omeprazole disposition and effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823233/),[h·pM] / [l],747,176907,DB00532,Mephenytoin
,8803522,total clearance,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),[ml] / [min],517,177431,DB00532,Mephenytoin
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,91,177432,DB00532,Mephenytoin
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,81,177433,DB00532,Mephenytoin
,8803522,elimination half-life,The elimination half-life was about 1 h.,Pharmacokinetics and absolute bioavailability of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),h,1,177434,DB00532,Mephenytoin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,88.3,177475,DB00532,Mephenytoin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,40.8,177476,DB00532,Mephenytoin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,127.8,177477,DB00532,Mephenytoin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,59.0,177478,DB00532,Mephenytoin
,23386533,limit of detection,The RP-HPLC assay showed good linearity (r(2) = 1.00) with 4-hydroxymephenytoin concentration from 0.100 to 50.0 μm and the limit of detection was 5.00 × 10(-2) μm.,Heterologous expression of human cytochrome P450 (CYP) 2C19 in Escherichia coli and establishment of RP-HPLC method to serve as activity marker. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23386533/),μm,5.00 × 10(-2),181208,DB00532,Mephenytoin
,23386533,Recovery,Recovery and accuracy of the assay were from 83.5 to 85.8% and from 95.0 to 105%.,Heterologous expression of human cytochrome P450 (CYP) 2C19 in Escherichia coli and establishment of RP-HPLC method to serve as activity marker. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23386533/),%,83.5 to 85.8,181209,DB00532,Mephenytoin
,8451774,total clearance,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],15.2,193421,DB00532,Mephenytoin
,8451774,total clearance,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],27.3,193422,DB00532,Mephenytoin
,8451774,total clearance,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.6,193423,DB00532,Mephenytoin
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],15.2,193424,DB00532,Mephenytoin
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],27.3,193425,DB00532,Mephenytoin
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.6,193426,DB00532,Mephenytoin
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],5.9,193427,DB00532,Mephenytoin
,8451774,dem,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],0.3,193428,DB00532,Mephenytoin
,8451774,dem,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.4,193429,DB00532,Mephenytoin
,8451774,clearance,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],0.3,193430,DB00532,Mephenytoin
,8451774,clearance,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.4,193431,DB00532,Mephenytoin
,8451774,metabolic ratio,"During administration of citalopram, there was a modest increase in sparteine metabolic ratio from median 0.31 to 0.80 in extensive metabolizers of sparteine, whereas the mephenytoin S/R ratio was unaltered during citalopram treatment.",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),,0.31,193432,DB00532,Mephenytoin
,8451774,metabolic ratio,"During administration of citalopram, there was a modest increase in sparteine metabolic ratio from median 0.31 to 0.80 in extensive metabolizers of sparteine, whereas the mephenytoin S/R ratio was unaltered during citalopram treatment.",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),,0.80,193433,DB00532,Mephenytoin
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],34.4,207703,DB00532,Mephenytoin
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],25.2,207704,DB00532,Mephenytoin
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[μg] / [h·l],8794,207705,DB00532,Mephenytoin
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[mg] / [h·l],"16,358",207706,DB00532,Mephenytoin
,18956271,IC(50),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.2,215833,DB00532,Mephenytoin
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,0.5,215834,DB00532,Mephenytoin
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215835,DB00532,Mephenytoin
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.9,215836,DB00532,Mephenytoin
,18956271,IC(50),"Similarly, beauvericin was also a potent inhibitor for CYP3A1/2 (IC(50): 1.3 microM) in RLM.",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215837,DB00532,Mephenytoin
,9366029,serum t1/2,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),h,47,226506,DB00532,Mephenytoin
,9366029,serum t1/2,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),h,35,226507,DB00532,Mephenytoin
,9366029,AUCss,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),[h·nM] / [l],"4,193",226508,DB00532,Mephenytoin
,9366029,AUCss,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),[h·nM] / [l],"2,562",226509,DB00532,Mephenytoin
,2612516,clearance,"The mean (+/- SD) clearance of R- and S-mephenytoin were 171 +/- 58 ml/hr (R) and 110 +/- 37 ml/hr (S), and the mean (+/- SD) volumes of distribution were 325 +/- 75 ml (R) and 359 +/- 72 ml (S).",Mephenytoin stereoselective elimination in the rat: I. Enantiomeric disposition following intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612516/),[ml] / [h],171,226512,DB00532,Mephenytoin
,2612516,clearance,"The mean (+/- SD) clearance of R- and S-mephenytoin were 171 +/- 58 ml/hr (R) and 110 +/- 37 ml/hr (S), and the mean (+/- SD) volumes of distribution were 325 +/- 75 ml (R) and 359 +/- 72 ml (S).",Mephenytoin stereoselective elimination in the rat: I. Enantiomeric disposition following intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612516/),[ml] / [h],110,226513,DB00532,Mephenytoin
,2612516,volumes of distribution,"The mean (+/- SD) clearance of R- and S-mephenytoin were 171 +/- 58 ml/hr (R) and 110 +/- 37 ml/hr (S), and the mean (+/- SD) volumes of distribution were 325 +/- 75 ml (R) and 359 +/- 72 ml (S).",Mephenytoin stereoselective elimination in the rat: I. Enantiomeric disposition following intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612516/),ml,325,226514,DB00532,Mephenytoin
,2612516,volumes of distribution,"The mean (+/- SD) clearance of R- and S-mephenytoin were 171 +/- 58 ml/hr (R) and 110 +/- 37 ml/hr (S), and the mean (+/- SD) volumes of distribution were 325 +/- 75 ml (R) and 359 +/- 72 ml (S).",Mephenytoin stereoselective elimination in the rat: I. Enantiomeric disposition following intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612516/),ml,359,226515,DB00532,Mephenytoin
,18294333,AUC(infinity),"The mean omeprazole AUC(infinity) of 1973 h nmol l(-1) in CYP2C19*17/*17 subjects was 2.1-fold lower [95% confidence interval (CI) 1.1, 3.3] than in CYP2C19*1/*1 subjects (4151 h nmol l(-1), P = 0.04).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],1973,227672,DB00532,Mephenytoin
,18294333,AUC(infinity),"The mean omeprazole AUC(infinity) of 1973 h nmol l(-1) in CYP2C19*17/*17 subjects was 2.1-fold lower [95% confidence interval (CI) 1.1, 3.3] than in CYP2C19*1/*1 subjects (4151 h nmol l(-1), P = 0.04).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],4151,227673,DB00532,Mephenytoin
,18294333,AUC(infinity),"A similar trend was observed for the sulphone metabolite with the CYP2C19*17/*17 group having a mean AUC(infinity) of 1083 h nmol l(-1), 3.1-fold lower (95% CI 1.2, 5.5) than the CYP2C19*1/*1 group (3343 h nmol l(-1), P = 0.03).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],1083,227674,DB00532,Mephenytoin
,18294333,AUC(infinity),"A similar trend was observed for the sulphone metabolite with the CYP2C19*17/*17 group having a mean AUC(infinity) of 1083 h nmol l(-1), 3.1-fold lower (95% CI 1.2, 5.5) than the CYP2C19*1/*1 group (3343 h nmol l(-1), P = 0.03).",Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294333/),[h·nM] / [l],3343,227675,DB00532,Mephenytoin
,8148222,Cmax,"The mean (s.d.) Cmax was 117 (81) nmol l-1 and the mean AUC(0,24) value was 890 (711) nmol l-1 h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),[nM] / [l],117,234385,DB00532,Mephenytoin
,8148222,"AUC(0,24)","The mean (s.d.) Cmax was 117 (81) nmol l-1 and the mean AUC(0,24) value was 890 (711) nmol l-1 h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),[h·nM] / [l],890,234386,DB00532,Mephenytoin
,8148222,"t1/2,z","The value of t1/2,z varied 3-fold with a mean (s.d.) of 13.3 (5.0) h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),h,13.3,234387,DB00532,Mephenytoin
,15842554,K(m),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),μm,121.7,235078,DB00532,Mephenytoin
,15842554,V(max),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[pM] / [mg·min],16.1,235079,DB00532,Mephenytoin
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[μl] / [min·nmol],0.26,235080,DB00532,Mephenytoin
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[μl] / [min·nmol],0.22,235081,DB00532,Mephenytoin
,15842554,nonrenal clearance,"In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.8,235082,DB00532,Mephenytoin
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.01,235083,DB00532,Mephenytoin
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,0.56,235084,DB00532,Mephenytoin
,3459864,Brain/plasma concentration ratio,"Brain/plasma concentration ratio of I was about 1.3, whereas that of II was about 0.05.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),,1.3,236528,DB00532,Mephenytoin
,3459864,Brain/plasma concentration ratio,"Brain/plasma concentration ratio of I was about 1.3, whereas that of II was about 0.05.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),,0.05,236529,DB00532,Mephenytoin
,3459864,Plasma protein binding,"Plasma protein binding of I having pKa value of 8.30 was about 88%, whereas that of II having pKa value of 4.89 was about 99%.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),%,88,236530,DB00532,Mephenytoin
,3459864,Plasma protein binding,"Plasma protein binding of I having pKa value of 8.30 was about 88%, whereas that of II having pKa value of 4.89 was about 99%.","Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459864/),%,99,236531,DB00532,Mephenytoin
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00532,Mephenytoin
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00532,Mephenytoin
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00532,Mephenytoin
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00532,Mephenytoin
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00532,Mephenytoin
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00532,Mephenytoin
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00532,Mephenytoin
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00532,Mephenytoin
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00532,Mephenytoin
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00532,Mephenytoin
,12968986,CT half-life,"Based on two time points, this subject had a very long CT half-life of 95 h.",Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968986/),h,95,246479,DB00532,Mephenytoin
,42344,time to peak concentration (Tmax),"The time to peak concentration (Tmax) for mephenytoin was 1 hour, with a half-life (T 1/2) of 7 hours; the T 1/2 of its metabolite, 5-ethyl-5-phenylhydantion, was 96 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,1,259166,DB00532,Mephenytoin
,42344,half-life (T 1/2),"The time to peak concentration (Tmax) for mephenytoin was 1 hour, with a half-life (T 1/2) of 7 hours; the T 1/2 of its metabolite, 5-ethyl-5-phenylhydantion, was 96 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,7,259167,DB00532,Mephenytoin
,42344,T 1/2,"The time to peak concentration (Tmax) for mephenytoin was 1 hour, with a half-life (T 1/2) of 7 hours; the T 1/2 of its metabolite, 5-ethyl-5-phenylhydantion, was 96 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,96,259168,DB00532,Mephenytoin
,42344,Tmax,"Ethotoin Tmax was 2 hours, with a T 1/2 of 5 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,2,259169,DB00532,Mephenytoin
,42344,T 1/2,"Ethotoin Tmax was 2 hours, with a T 1/2 of 5 hours.",Clinical pharmacology of mephenytoin and ethotoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42344/),h,5,259170,DB00532,Mephenytoin
,11936706,clearance,"The mean clearance of R-ketamine, 0.020 l min(-1) kg(-1), was slightly but significantly lower than of S-ketamine, 0.024 l min(-1) kg(-1).",Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936706/),[l] / [kg·min],0.020,260954,DB00532,Mephenytoin
,11936706,clearance,"The mean clearance of R-ketamine, 0.020 l min(-1) kg(-1), was slightly but significantly lower than of S-ketamine, 0.024 l min(-1) kg(-1).",Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936706/),[l] / [kg·min],0.024,260955,DB00532,Mephenytoin
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,100.8,261726,DB00532,Mephenytoin
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,219.9,261727,DB00532,Mephenytoin
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,34.7,261728,DB00532,Mephenytoin
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,103.1,261729,DB00532,Mephenytoin
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,30.8,261730,DB00532,Mephenytoin
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,103.1,261731,DB00532,Mephenytoin
,11294510,Urinary excretion,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),%,12.5,262384,DB00532,Mephenytoin
,11294510,Urinary excretion,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),%,7.7,262385,DB00532,Mephenytoin
,11294510,formation clearance,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],29.8,262386,DB00532,Mephenytoin
,11294510,formation clearance,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],21.1,262387,DB00532,Mephenytoin
,11294510,area under the serum concentration-time curve,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[h·μg] / [ml],153.3,262388,DB00532,Mephenytoin
,11294510,area under the serum concentration-time curve,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[h·μg] / [ml],122.9,262389,DB00532,Mephenytoin
,11294510,total,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],210.8,262390,DB00532,Mephenytoin
,11294510,total,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],254.9,262391,DB00532,Mephenytoin
,11294510,renal clearance,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],53.1,262392,DB00532,Mephenytoin
,11294510,renal clearance,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],66.1,262393,DB00532,Mephenytoin
,11294510,hydroxylation index,"The mephenytoin hydroxylation index did not change in either EMs (1.42 versus 1.42) or PMs (341.4 versus 403.5), showing that CYP2C19 was not induced by treatment with PB.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),,1.42,262394,DB00532,Mephenytoin
,11294510,hydroxylation index,"The mephenytoin hydroxylation index did not change in either EMs (1.42 versus 1.42) or PMs (341.4 versus 403.5), showing that CYP2C19 was not induced by treatment with PB.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),,341.4,262395,DB00532,Mephenytoin
,11294510,hydroxylation index,"The mephenytoin hydroxylation index did not change in either EMs (1.42 versus 1.42) or PMs (341.4 versus 403.5), showing that CYP2C19 was not induced by treatment with PB.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),,403.5,262396,DB00532,Mephenytoin
,7619672,elimination half-life (t 1/2),2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),h,20.6,264839,DB00532,Mephenytoin
,7619672,elimination half-life (t 1/2),2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),h,14.6,264840,DB00532,Mephenytoin
,7619672,AUC,2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),h,14.6,264841,DB00532,Mephenytoin
,7619672,AUC,2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],5.43,264842,DB00532,Mephenytoin
,7619672,AUC,2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],3.68,264843,DB00532,Mephenytoin
,7619672,"AUC(0,24 h)","Mean AUC(0,24 h) values of CPB were significantly (P < 0.05) lower in the PM (n = 4) than in the EM group (n = 14) (0.47 +/- 0.13 vs 0.88 +/- 0.50 (-0.14 to 0.96) micrograms ml-1 h).",Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],0.47,264844,DB00532,Mephenytoin
,7619672,"AUC(0,24 h)","Mean AUC(0,24 h) values of CPB were significantly (P < 0.05) lower in the PM (n = 4) than in the EM group (n = 14) (0.47 +/- 0.13 vs 0.88 +/- 0.50 (-0.14 to 0.96) micrograms ml-1 h).",Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],0.88,264845,DB00532,Mephenytoin
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],95.6,267028,DB00532,Mephenytoin
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],160.4,267029,DB00532,Mephenytoin
,9014204,hydroxylation ratio,Thirteen subjects (12.6%) were identified as poor metabolizers (PMs) with an omeprazole hydroxylation ratio of 6.95 or higher.,CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9014204/),,6,267271,DB00532,Mephenytoin
,12973371,bioavailability,"Pantoprazole, a second-generation proton pump inhibitor, is absorbed after oral administration as enteric-coated tablet with maximum plasma concentrations within 2-3 h and a bioavailability of 77%.",Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973371/),%,77,272764,DB00532,Mephenytoin
,12973371,half-life,"The pharmacokinetic profile is practically unchanged after multiple dosing, as is expected for a drug with a short half-life of about 1 h.",Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973371/),h,1,272765,DB00532,Mephenytoin
